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Abstract Polycystic ovary syndrome (PCOS) is a com-
mon disorder affecting between 5 and 18 % of females of
reproductive age and can be diagnosed based on a com-
bination of clinical, ultrasound and biochemical features,
none of which on its own is diagnostic. A lipidomic
approach using liquid chromatography coupled with
accurate mass high-resolution mass-spectrometry (LC-
HRMS) was used to investigate if there were any differ-
ences in plasma lipidomic profiles in women with PCOS
compared with control women at different stages of men-
strual cycle. Plasma samples from 40 women with PCOS
and 40 controls aged between 18 and 40 years were ana-
lysed in combination with multivariate statistical analyses.
Multivariate data analysis (LASSO regression and OPLS-
DA) of the sample lipidomics datasets showed a weak
prediction model for PCOS versus control samples from
the follicular and mid-cycle phases of the menstrual cycle,
but a stronger model (specificity 85 % and sensitivity
95 %) for PCOS versus the luteal phase menstrual cycle
controls. The PCOS vs luteal phase model showed
increased levels of plasma triglycerides and sphingomye-
lins and decreased levels of lysophosphatidylcholines and
phosphatidylethanolamines in PCOS women compared
with controls. Lipid biomarkers of PCOS were tentatively
identified which may be useful in distinguishing PCOS
from controls especially when performed during the men-
strual cycle luteal phase.
Keywords Polycystic ovary syndrome  Lipidomics 
Biomarkers  Menstrual cycle
1 Introduction
Polycystic ovary syndrome (PCOS) remains an enigma,
despite the fact that it affects 5–18 % of females of
reproductive age (Dunaif 1997; Legro et al. 1998; March
et al. 2010). The heterogenous disorder is characterized by
chronic oligo-anovulation, and hyperandrogenaemia,
associated with morphologically abnormal ovaries with
numerous small follicular cysts (Banaszewska et al. 2006).
Most symptoms of PCOS are irregular or non-existent
period, very light and very heavy bleeding during period,
infertile, over weight (Bogdonov et al. 2008). Although
significant progress has been made in our understanding of
PCOS, there are still challenges in unravelling its com-
plexity. The diagnosis of PCOS is based on a combination
of clinical, ultrasound and biochemical features, none of
which on its own is diagnostic (Rotterdam ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group 2004); a
single unifying mechanism has yet to be found. New
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experimental approaches are therefore required to help
address some of the scientific and clinical challenges
(Pasquali et al. 2011; Atiomo et al. 2009a, b). In PCOS,
genomic, proteomic and more recently metabolomic stud-
ies (Urbanek et al. 1999; Hughes et al. 2006; Luque-Ra-
mirez and San Millan 2006; Goodarzi 2008; Chen et al.
2011; Matharoo-Ball et al. 2007; Ma et al. 2007; Choi et al.
2007; Corton et al. 2008; Insenser et al. 2010; Atiomo and
Daykin 2012; Zhao et al. 2012) have identified new path-
ways and molecular targets that offer promise in unravel-
ling the complexity of PCOS.
A number of human diseases are linked with abnormal
lipid metabolism including obesity, atherosclerosis, dia-
betes and fatty liver disease (Han et al. 2000; Kim et al.
2010; Reddy and Rao 2006) and it is likely that metabolic
dysfunction observed in PCOS will result in the genera-
tion of lipid biomarkers of the disease in blood. The
emergence of lipidomics as a distinct field (Wenk 2005),
coupled with the advancement of new analytic platforms
(Quehenberger and Dennis 2011) offer new opportunities
to investigate changes in lipid profiles from patients
compared to controls so as to determine biologically
significant deviations from the norm. The global view of
lipid metabolism offered by lipidomics has the potential
to improve our understanding of PCOS disease processes
(Meikle and Christopher 2011) and could potentially
introduce new biomarkers into clinical practice for early
diagnosis of disease and improved patient management
(Postle 2012).
In a recent metabolomics study, Zhao et al. (2012) found
changed levels of carbohydrates, amino acids and lipids in
PCOS patients. Specifically, they noted that the levels of
long-chain fatty acids, triglycerides and very low-density
lipoprotein were elevated, while phosphatidylcholine and
HDL concentrations were reduced in PCOS patients as
compared with controls. The aim of this study was further
investigate these distinctive changes in the plasma lipid
profiles between women with PCOS and controls using
validated lipidomics methodology.
2 Materials and methods
2.1 Reagents and materials
A Milli-Q water purification system (Millipore, MA, USA)
was used in the preparation of deionized water (18.2 MX).
Acetonitrile and chloroform were HPLC grade purchased
from Fischer Scientific (Loughborough, UK). Methanol
(LC–MS grade) and ammonium acetate were purchased
from Sigma-Aldrich (Dorset, UK). Isopropanol (LC–MS
grade) and ethanol AR grade were obtained from Fischer
Scientific (Loughborough, UK). Lipid chemical standards
(including eicosanoids, endocannabinoids and prostaglan-
dins, listed in full in the Supplementary information Table
S1) were purchased from Axxora (Bingham, UK) and IDS
PLC (Boldon, UK).
2.2 Sample collection
2.2.1 Ethics approval and study design
Ethics committee (Institutional review board) approval
was obtained for this study from the UK East Midlands
Health Research Authority, Research Ethics Committee
(REC reference 10/H0408/69). This was a cross-sectional
study at the University hospital department of Obstetrics
and Gynaecology at the Queen’s Medical Centre Cam-
pus, Nottingham University Hospitals NHS Trust, Not-
tingham, in which 40 women with PCOS and 40 controls
aged between 18 and 40 years were prospectively
recruited.
2.2.2 Recruitment of participants and controls
PCOS was defined as women with two or more of the
following in the absence of other endocrine causes of
oligo-and/or anovulation (Rotterdam ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group 2004):
oligo-and/or anovulation, clinical and/or biochemical signs
of hyperandrogenism and polycystic ovary (PCO) mor-
phology on ultrasound scan. Clinical evidence of hyper-
androgenism was defined as clinical history of hirsutism
and biochemical evidence of hyperandrogenism was
defined as a free androgen index of 5 or more. Age mat-
ched women without PCOS who had regular 21–35 day
menstrual cycles were used as controls. Controls were
identified from patients and female members of staff who
volunteered to participate. Specific inclusion criteria for
controls included the following; regular 21–35 day men-
strual cycles, no ultrasound evidence of PCO, no evidence
of hyperandrogenism and not currently using hormonal
contraception. Women with PCOS were identified from the
gynaecology/endocrine and the fertility clinics at the
Queen’s Medical Centre, Nottingham. Women with PCOS
who met the inclusion criteria were approached verbally or
in writing, asking if they would like to participate in this
study. A patient information sheet was provided and fol-
lowing informed consent, they were recruited into the
study. Women with PCOS or controls with any of the
following were excluded from the study: thyroid disease,
current pregnancy, delivery or miscarriage occurring
within the preceding 3 months, recent surgery (within
3 months), history of myocardial infarction, use of aspirin
or heparin, sex steroid therapy, a history of haematological
disease, malignancy or liver disease, hyperprolactinaemia,
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a history of thrombosis and recent viral illness. No body
mass index limits were a pre-requisite for inclusion or
exclusion. Amongst the women with PCOS, five women
had a history of asthma, one had hypertension, one had
clinical depression, one had hypothyroidism and one had
sleep apnoea. Amongst the controls, two women had a
history of asthma, two had uterine fibroids, one had mitral
valve prolapse, one eczema, one psoriasis, one clinical
depression and one trigeminal neuralgia. With respect to
medicament ingest, amongst the women with PCOS, four
were using asthma inhalers, one was on ramipril, one was
on thyroxin, one was on amitriptyline and two were on
folic acid. Amongst the controls, two women were on
asthma inhalers, one on gabapentin and one was on Prozac.
With respect to diet, all women were fasted before blood
samples were collected. We did not collect any data on
whether or not women were vegetarian or not.
2.2.3 Interventions
Women were invited into the hospital where the following
interventions occurred. A clinical interview was under-
taken to elicit the reproductive, medical, drug, family and
social histories. Anthropometric measurements for height,
weight, body mass index (BMI), waist and hip circumfer-
ence were obtained. Fasting blood samples were then taken
for endocrine (testosterone, sex hormone binding globulin,
luteinising hormone, follicle stimulating hormone, thyroid
function tests, 17-hydroxyprogesterone, prolactin, insulin,
glucose, cholesterol, triglycerides and high density lipo-
proteins) and lipidomic assays and a pelvic ultrasound was
performed to measure the endometrial thickness, ovarian
follicle count, size and blood flow. Women with PCOS
were invited once in for the fasting blood tests and ultra-
sound scans. PCOS samples were taken once on any day of
the menstrual cycles because of the menstrual irregularity
associated with PCOS. Control women without PCOS were
however invited three times in their menstrual cycles
(follicular, mid cycle and secretory phase) to enable an
evaluation of cycle variability in the lipid profiles. Fasting
blood samples were collected in pre-chilled lithium heparin
tubes and centrifuged within 30 min at 2,0009g and 4 C
for 10 min. Plasma was separated and immediately stored
at -80 C until analysis.
2.3 Sample preparation
Lipids were extracted from plasma samples (50 lL) by
adding 0.5 mL of cold (-20 C) chloroform/methanol
(1:2), the frozen plasma sample being allowed to thaw in
the presence of the extraction solvent. After brief vortex-
mixing (20 s), 0.5 mL of water was added and the tube
contents mixed again for 10 min, centrifuged at
1,0009g for 10 min at 4 C. An aliquot of the lower
lipophilic phase (100 lL) was removed and mixed with an
equal volume of isopropanol prior to analysis. A pooled
QC sample was prepared by mixing 20 lL aliquots taken
from each individual plasma study sample and treated
exactly as described for the study samples.
2.4 Liquid chromatography-mass spectrometry
lipidomic analysis
2.4.1 Chromatography
Chromatographic separations were performed on an ACE 3
C18 HPLC column (150 9 2.1 mm, 3 lm particle size;
Aberdeen, UK) maintained at a temperature of 40 C and a
flow rate of 300 lL/min. Mobile phases consisted of
(A) 60:40 acetonitrile:10 mM aqueous ammonium acetate
and (B) 90:10 isopropanol:10 mM ammonium acetate in
acetonitrile. A binary gradient from 30 to 97 % B was used
with a total run time of 15 min. The injection volume was
10 lL.
2.4.2 Mass spectrometry
Mass spectrometry was performed on an Orbitrap Exac-
tive MS (Thermo Fisher Scientific, USA) acquiring data
simultaneously in full scan ion mode (m/z 100–1200,
resolution 25,000, AGC 1e6) in both positive and nega-
tive modes. The capillary voltage was maintained at
25 V in the positive ion mode and at 27 V in the neg-
ative ion mode. All other interface settings used were
same for both positive and negative modes. The voltages
of tube lens and skimmer in positive mode were set to
115 and 22 V respectively. Negative mode voltages of
tube lens and skimmer were set to 140 and 28 V
respectively. The flow rates of sheath gas, auxillary gas
and sweep gas for both positive negative modes were
adjusted to 30, 15 and 5 (arbitrary units). The capillary
temperature and heater temperature were maintained at
350 and 300 C respectively in both positive and nega-
tive modes.
2.5 Data analysis and metabolite identification
Raw LC–MS data from the PCOS and control group
samples were acquired using Xcalibur v2.1 software
(Thermo Scientific, Hemel Hemstead UK), the control
groups including samples from each of the three phases of
the menstrual cycle (follicular, mid-cycle and secretory).
The raw data for each sample analysis consisted of 5–8,000
resolvable LC–MS signals identified by m/z, retention time
and ion signal intensity. The full datasets from PCOS group
and the control groups were imported and pre-processed by
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Progenesis CoMet v.1.2 software (Nonlinear Dynamics,
Newcastle upon Tyne, UK). The performance of the ana-
lytical method was validated by monitoring a representa-
tive set of plasma lipids in pooled quality control (QC)
samples for retention time-shifts, relative standard devia-
tions (RSD%) of peak areas and mass accuracy. Multi-
variate data analysis was used to investigate changes in the
plasma-lipid profiles between the PCOS and individual
menstrual cycle datasets using principal component ana-
lysis (PCA), orthogonal partial least squares discriminant
analysis (OPLS-DA) using SIMCA-P v12 (Umetrics,
Umea, Sweden) and Logistic Lasso regression from the R
package glmnet (Friedman et al. 2010). Initial models
based on the entire datasets (n = 40) were cross validated
(leave one out method) and further prediction models were
based on randomly selected training (n = 20) and test sets
(n = 20) with sensitivity and specificity calculations
reported. Any biomarkers associated with BMI were then
excluded from the final model to eliminate the potential
confounding effects of obesity. Tentative identification of
key lipid biomarkers was achieved by using accurate mass
determinations within a narrow m/z range (1–5 mDa) to
search appropriate metabolite databases: lipid maps (http://
www.lipidmaps.org/) and the Human Metabolome data-
base (http://www.hmdb.ca/).
3 Results
3.1 Demographic data
Table 1 shows the demographic and endocrine features of
the 40 selected women with PCOS compared with 40
controls. Samples taken in the follicular phase from con-
trols were analysed for endocrine data. There was no sig-
nificant difference in the ages of both groups. However
women with PCOS had a significantly higher BMI, LH,
testosterone and free androgen index and lower FSH levels
as consistent with the diagnosis of PCOS.
3.2 Validation of LC–MS lipidomic method
performance
The analytical performance of the LC–MS lipidomics
method was evaluated using QC samples pooled from
aliquots of each study sample. All sample and QC extracts
were analysed in a single LC–MS run with pooled QC
samples being interspaced with study samples. The pooled
QC samples were tightly clustered by PCA analysis
(Fig. 1). In the QC datasets the % RSD values of peak
areas of selected typical plasma lipids were in the range of
7.6–13.2 %, retention time shifts were less than 0.07 min,
Table 1 Demographic and endocrine data comparing PCOS to controls
Variable mean (±SD) PCOS N = 40 Controls N = 40 p value q value
Age (years) 29.2 (4.5) 30.6 (5.0) 0.26 0.36
BMI (kg/m2) 29.5 (6.1) 25.4 (5.9) 7.4 9 10-4 3.2 9 10-3*
LH (IU/L) 13.8 (11.6) 5.20 (2.40) 3.9 9 10-7 6.7 9 10-6*
FSH(IU/L) 5.69 (2.87) 7.50 (3.73) 1.4 9 10-3 4.9 9 10-3*
Testosterone (mmol/L) 2.18 (0.76) 1.47 (0.54) 2.5 9 10-5 2.1 9 10-4*
SHBG (nmol/L) 52.8 (29.9) 61.6 (26.7) 0.068 0.17
Free androgen index 5.03 (2.91) 2.56 (1.77) 5.8 9 10-5 3.3 9 10-4*
PRL (pmol) 225 (122) 193 (78) 0.33 0.41
TSH (mlU/L) 1.85 (1.06) 2.37 (1.33) 0.024 0.069
FT4 (pmol/L) 15.5 (3.0) 15.1 (1.9) 0.83 0.83
17-OHP (nmol/L) 6.76 (5.65) 4.84 (2.75) 0.28 0.36
Fasting insulin (lU/mL) 7.18 (6.21) 5.15 (5.54) 0.092 0.20
Fasting glucose (mmol/L) 4.54 (0.42) 4.66 (0.44) 0.22 0.36
Insulin/glucose ratio 1.40 (1.18) 1.22 (1.22) 0.25 0.36
Cholesterol (mmol/L) 4.49 (0.78) 4.84 (0.82) 0.49 0.52
TG (mmol/L) 1.00 (0.57) 0.835 (0.297) 0.20 0.36
HDL (mmol/L) 1.51 (0.31) 1.58 (0.31) 0.38 0.43
SD standard deviation, BMI body mass index, SHBG sex hormone binding globulin, FAI free androgen index, LH luteinising hormone, FSH
follicle stimulating hormone, PRL prolactin, TSH thyroid stimulating hormone, FT4 free thyroxine, 17-OHP 17 hydroxy progesterone, TG
triglycerides, HDL high density lipoproteins
p values have been calculated using the non-parametric Mann–Whitney test as many measures are not normally distributed. q value corrections 22
are included to correct for multiple testing and are more indicative of significance; measures with significant differences (q value\0.05) have
been marked with a *
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the mass accuracy deviation was less than 1 mDa in
positive ion mode and less than 2 mDa in negative ion
mode (Supplementary Information Table S2). These results
validate the LC–MS lipidomics analytical performance
during the analysis of the study samples. Typical LC–MS
chromatograms obtained from plasma extracts are shown
in Fig. 2.
3.3 Plasma lipidomics analysis of PCOS and menstrual
cycle control samples
Complete LC–MS lipidomics datasets were obtained for
the PCOS samples (n = 40) and the control samples at the
follicular (n = 40), mid-cycle (n = 40) and luteal
(n = 40) phases of the menstrual cycle. No differences in
Fig. 1 Overview PCA scores
plot obtained from all PCOS
samples (red circles, n = 40),
all control samples (green
circles, n = 120) and all pooled
QC samples (black squares,
n = 9). (R2X = 0.654,
Q2 = 0.285, A = 24, total
N = 169) (Color figure online)
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Fig. 2 The total ion LC-HRMS chromatogram of a typical PCOS plasma sample extracted with chloroform/methanol in negative (upper) and
positive (lower) ionisation modes. All the chromatograms were recorded in the range of m/z 100–1,200
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plasma lipid profiles could be distinguished between the
three control samples sets from different stages of the
menstrual cycle using multivariate data analysis. Using
supervised multivariate data analysis methods of Lasso
regression analysis and OPLS-DA, it was possible to build
cross-validated models based on small differences in lipid
profiles which could predict between individuals with
PCOS and control samples at each stage of the menstrual
cycle using the lipidomics datasets (OPLS-DA scores plot,
Fig. 3). These models were evaluated by monitoring the
goodness of model (R2X) and predictive ability (Q2) val-
ues. OPLS-DA model comparing between PCOS and luteal
cycle gave better R2X and Q2 values (0.417 and 0.512
respectively) than PCOS vs follicular-cycle control groups
(R2X = 0.389, Q2 = 0.259) or PCOS vs mid-cycle con-
trol groups (R2X = 0.314, Q2 = 0.225). Where certain
PCOS biomarkers were associated with BMI (as was the
case with PCOS vs luteal phase controls) these were
excluded from the models. However, when a more strin-
gent model validation process was applied involving ran-
domly selected training (n = 20) and test sets (n = 20)
only with the PCOS vs luteal phase samples was a valid
disease model confirmed (Fig. 4, OPLS-DA example). The
results of multivariate data analysis and the specificity and
sensitivity of the models generated are shown in Table 2.
Overall, the two multivariate data analysis methods, OPLS-
(A)
(B)
(C)
Fig. 3 OPLS-DA scores plot obtained between all PCOS samples
(red circles, n = 40) and a control follicular-cycle samples (black
circles, n = 40) (R2X = 0.389, R2Y = 0.939, Q2 = 0.259,
A = 1 ? 4 ? 0); b Control mid-cycle samples (blue circles,
n = 40) (R2X = 0.314, R2Y = 0.759, Q2 = 0.225, A = 1 ?
! 2 ? 0) and c control luteal-cycle samples (green circles, n = 40).
(R2X = 0.417, R2Y = 0.953, Q2 = 0.512, A = 1 ? 4 ? 0) (Color
figure online)
A
(B)
(A)
Fig. 4 a OPLS-DA scores plot (test set) obtained from a random
selection of 50 % PCOS (red circles) and control luteal-cycle (green
circles) samples. Model was built using a training set constructed
from the complementary control and PCOS sample data.
(R2X = 0.367, R2Y = 0.979, Q2 = 0.569, A = 1 ? 3 ? 0,
N = 40). b OPLS-DA scores plot obtained based on potential
biomarkers only from PCOS samples (red circles) and control luteal-
cycle samples (green circles) (R2X = 0.634, R2Y = 0.903,
Q2 = 0.739, A = 1 ? 3 ? 0, N = 40) (Color figure online)
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DA and LASSO regression, gave similar results. In addi-
tion, a permutation test (n = 100) was conducted to eval-
uate the prediction model (Fig. 5) and the Q2-intercept
value (-0.27) from the prediction model at less than 0.05
shows that the good predictive ability of the model was not
because of over-fitting of the model to the complex data
sets. Moreover, the model was validated by calculating
area under receiver operating characteristic (ROC) curve
(Eng 2007). The value of area under curve (AUC) was 0.95
which gives added confidence of the model (Fig. 6).
3.4 Plasma lipid biomarkers of PCOS
The greatest differences in the plasma lipid profiles were
observed between the PCOS and luteal menstrual cycle
control groups in both Lasso regression and OPLS-DA
models. Potential lipid biomarkers were therefore derived
from the mass spectrometry m/z variables which had the
most significant contribution to both of these models
(Table 3). These m/z variables, which are derived from the
high resolution mass spectrometry data obtained from the
lipidomics analysis, are represented as an accurate mass of
an individual lipid (generally to within 1–2 mDa) and have
undergone deconvolution to remove adducts, isotopes and
other confounding factors resulting from mass spectrome-
try detection. The exact mass of the biomarkers coupled
with derived empirical molecular formula were then used
to interrogate appropriate metabolic databases and to pro-
vide tentative identification of the lipid species. The top 25
lipid species are shown in Table 3 together with a struc-
tural code from Lipid Maps (http://www.lipidmaps.org/) or
the Human Metabolome database (http://www.hmdb.ca/).
Plasma samples of PCOS patients were distinguished
from the luteal menstrual cycle control plasma by a com-
bination of small changes in lipid composition. Lipid bio-
markers which were consistently increased or decreased in
Table 2 Prediction of PCOS
status based on OPLS-DA and
LASSO regression models
Analysis
method
Datasets used Cross-validated model Training/test model
Sensitivity
(%)
Specificity
(%)
Sensitivity
(%)
Specificity
(%)
Lasso
regression
PCOS vs follicular 80 72.5 70 50
PCOS vs mid-
cycle
62.5 60 55 40
PCOS vs luteal 97.5 100 85 95
OPLS-DA PCOS vs follicular 92.5 90 55 75
PCOS vs mid-
cycle
60 65 45 65
PCOS vs luteal 100 100 85 95
Fig. 5 Validation plot obtained from permutation test (n = 100) for
the OPLS-DA model of PCOS versus luteal phase. R2 is the
explained variance, and Q2 is the predictive ability of the model. The
Q2-intercept value was less than 0.05 shows that the model is
statistically sound and high predictability of the model is not because
of over-fitting data
Fig. 6 ROC curve is defined as true positive fraction versus false
positive fraction. To affirm the validity of prediction OPLS-DA
model of PCOS vs luteal phase, area under receiver operating
characteristic (ROC) curve was calculated. The area under the curve
was 0.95 (an ideal model would have an AUC of 1) which clearly
states that the prediction model was robust. TPF true false positive,
upper upper 95 % confidence interval values and lower lower 95 %
confidence interval values
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women with PCOS included increases in triglycerides (TG)
and sphingomyelins (SM) and decreases in lys-
ophosphatidylcholines (LysoPC) and phosphatidylethano-
lamines (PE) (Table 3). Some lipids in the model (PC
phosphatidylcholine; DG diacylglycerol) had both
increased and decreased fragment ions of the same lipid
families (Table 3).
4 Discussion
As previously observed by Zhao et al. (2012) we did not
find a single lipid biomarker in plasma for PCOS, but rather
there was a pattern of change in the plasma lipid profiles
which distinguished the control group from the PCOS
patients. The observed changes in our study were relatively
small, requiring detailed multivariate data-analysis to sep-
arate the PCOS group from the controls. The strengths of
our study are the rigorous validation methods used in the
data analysis to minimise the risks of false positives and the
use of validated LC-HRMS for ensured a high sensitivity
and specificity. Plasma samples of PCOS patients showed
significantly increased levels of mainly membrane lipids
including triglycerides and sphingomyelins, and decreased
levels of lysophosphatidylcholines and phosphatidyletha-
nolamines when PCOS samples were compared with con-
trol samples taken in the luteal phase of the menstrual cycle
which is consistent with the changes in lipids observed by
Zhao et al. (2012).
It is currently not clear why the differences identified in
the study were much more prominent in comparisons
between PCOS and controls samples taken in the luteal
phase of the menstrual cycle, it may however be a reflec-
tion of biochemical changes which occur following ovu-
lation in the luteal phase of the menstrual cycle in most
women with regular menstrual cycles in contrast to
anovulatory women with PCOS. We could not identify any
previously published studies investigating the variation of
sphingomyelins lysophosphatidylcholines and phosphati-
dylethanolamines in the menstrual cycle, but there had
been previous studies on triglycerides, in which the data
appeared conflicting. In one study (Punnonen 1978), of ten
healthy women with regular menstrual cycles tested for
levels of total serum cholesterol, triglycerides,
Table 3 Biomarkers showing
differences between PCOS
patients and luteal phase control
subjects
Mass difference (mDa) is the
difference in exact
monoisotopic mass between the
measured value and the
theoretical value
PC phosphatidylcholine, DG
diacylglycerol, TG triglyceride,
SM sphingomyelin, PE
phosphatidylethanolamine,
LysoPC
lysophosphatidylcholine
:; increase or decrease of
biomarker in PCOS group
compared with luteal control
group
Biomarker
MW (Da)
Formula Mass
difference
(mDa)
Lipid tentative
identification
OPLS-DA
analysis
Lasso
regression
analysis
PCOS
change
;:
286.2297 C20H30O 0.61 Unknown 4 4 :
351.2443 C17H37NO4S 4.70 Unknown 4 4 :
716.4992 C39H73O9P 0.50 Unknown 4 4 :
829.6561 C47H92NO8P 1.70 PE (42:1) 4 4 ;
725.4995 C40H72NO8P 1.50 PC (32:4) 4 4 ;
691.5516 C38H78NO7P 1.20 Plasmalogen
(30:0)
4 4 ;
757.2191 C33H41O20 2.90 Unknown 4 4 :
815.5829 C48H82NO7P 1.90 Plasmalogen
(40:7)
4 4 :
620.5379 C39H72O5 0.002 DG (36:2) 4 4 :
608.538 C38H72O5 1.70 Unknown 4 4 :
936.8146 C61H108O6 0.28 TG (58:5) 4 :
910.7989 C59H106O6 0.73 TG (56:4) 4 :
754.5989 C43H83N2O6P 1.14 SM (d18:0/20:2) 4 :
876.7206 C57H96O6 1.90 TG (54:7) 4 :
868.752 C56H100O6 0.68 TG (52:4) 4 :
820.7519 C53H104O5 1.68 TG (50:0) 4 :
618.5223 C39H70O5 0.25 DG (36:3) 4 :
732.6145 C41H85N2O6P 1.30 SM (d18:0/18:0) 4 :
705.5308 C38H76NO8P 0.86 PC (30:0) 4 ;
719.5465 C39H78NO8P 1.01 PE (34:0) 4 ;
495.3324 C24H50NO7P 0.67 LysoPC (16:0) 4 ;
519.3324 C26H50NO7P 0.24 LysoPC (18:2) 4 ;
521.3481 C26H52NO7P 0.58 LysoPC (18:1) 4 ;
523.3637 C26H54NO7P 0.07 LysoPC (18:0) 4 ;
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phospholipids, and estradiol three times during one men-
strual cycle (during menstruation, at ovulation, and in the
luteal phase), lipid variations during the menstrual cycle
were minimal and serum cholesterol, triglycerides, and
phospholipids did not correlate with changes in the serum
estradiol levels. On the other hand, two studies were
identified showing lower triglyceride levels in the luteal
phase of the menstrual cycle compared to the mid-follicular
phase (Mumford et al. 2010) or menses (Woods and Gra-
ham 1986). Another possible explanation for these results
includes the possibilities of type 1 or type 2 statistical
errors, and only a repeat study on larger cohorts of patients
would clarify this.
The pattern of changes in some of the lipid profiles
observed may however not be inconsistent with the PCOS
phenotype. The finding of increased plasma triglyceride
levels for example was consistent with previously pub-
lished studies (Zhao et al. 2012; Wild et al. 2011) on
plasma lipid changes in PCOS. Sphingomyelin is found in
animal cell membranes, especially in the membranous
myelin sheath that surrounds some nerve cell axons, and is
thought to have a role in signal transduction (Kolesnick
1994). In a recently published study of metabolomic pro-
filing of plasma from women with PCOS compared with
controls of a similar body mass index using proton NMR
metabolomics, a signal was identified in the NMR spectra
that was thought to be possibly consistent with a higher
plasma level of sphingomyelin (Sun et al. 2012). Lyso-
phosphatidylcholine is a minor phospholipid in the cell
membrane but is present in significant amounts in the blood
plasma (Munder et al. 1979). Reduced lys-
ophosphatidylcholines have as far as we know not been
previously found in women with PCOS. Lys-
ophosphatidylcholines (LPC) (Munder et al. 1979) are
however derived from partial hydrolysis of phosphat-
idylcholines which have been shown to be reduced in
women with PCOS compared with controls (Zhao et al.
2012; Sun et al. 2012).
In our study BMI was higher in PCOS compared with
control patients which could be perceived as non-ideal,
however there is debate about the use of BMI matching in
PCOS studies. For example Bloom et al. (2007)argued that
matching did not offer advantages over independent con-
trol selection with regard to study validity (i.e., con-
founding bias) and our data partially supports this in that
there was no obvious variation identified when the lipid
profiles taken from control women in the three different
phases of the menstrual cycle were compared with each
other. This provided further justification the random timing
of blood tests in the PCOS group in addition to the fact that
irregular menstrual cycles in women with PCOS would
have made it impossible to perform similar repetitive blood
tests. In addition, other surrogate markers of the obesity
including insulin, glucose, insulin/glucose ratios, HDL
cholesterol and triglycerides were not significantly differ-
ent in women with PCOS compared with controls in our
study. This was further supported by the results of Lasso
regression analysis which showed that the predictive
models were independent of BMI.
The clinical significance of this study is that we have
identified a panel of potential lipid biomarkers of PCOS
which may be useful in distinguishing them from controls
especially when performed during the menstrual cycle
luteal phase. It is hoped that the publication of this study
will stimulate interest in this area by independent research
groups and encourage further validation of lipid metabo-
lites and pathways altered in PCOS.
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